Cover Image
市場調查報告書

Genmab A/S:產品平台分析

Genmab A/S - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 214158
出版日期 內容資訊 英文 43 Pages
訂單完成後即時交付
價格
Back to Top
Genmab A/S:產品平台分析 Genmab A/S - Product Pipeline Review - 2016
出版日期: 2016年04月20日 內容資訊: 英文 43 Pages
簡介

Genmab A/S,是專門創造與開發癌症治療使用的分化型人類抗體治療藥的生物科技企業。

本報告提供Genmab A/S的治療用開發中產品的開發情形調查分析,研究、開發概要,開發中產品的概要,臨床實驗的各階段的產品概要,藥物簡介,開發平台分析,企業資料等相關的系統性資訊。

目錄

Genmab A/S概要

Genmab A/S - 研究、開發概要

  • 主要治療領域

Genmab A/S - 開發平台檢驗

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Genmab A/S - 開發中產品的概要

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 在前臨床階段的產品/聯合治療模式

Genmab A/S - 藥物簡介

  • teprotumumab
  • tisotumab vedotin
  • HuMax-AXL-ADC
  • IDD-004
  • 中樞神經系統疾病的單株抗體 1
  • 中樞神經系統疾病的單株抗體 2
  • 中樞神經系統疾病的單株抗體 3
  • 腫瘤學的單株抗體 1
  • 腫瘤學的單株抗體 2
  • 腫瘤學的單株抗體複合體

Genmab A/S - 開發平台分析

  • 開發中產品:各標的
  • 開發中產品:各給藥途徑
  • 開發中產品:各分子類型
  • 開發中產品:各作用機制

Genmab A/S - 開發中產品的最新趨勢

Genmab A/S - 暫停的計劃

HuMax-CD74-ADC teprotumumab

Genmab A/S - 中止的開發中產品

Genmab A/S - 企業發表

Genmab A/S - 所在地與子公司

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08026CDB

Summary

Global Markets Direct's, 'Genmab A/S - Product Pipeline Review - 2016', provides an overview of the Genmab A/S's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Genmab A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Genmab A/S
  • The report provides overview of Genmab A/S including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Genmab A/S's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Genmab A/S's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Genmab A/S's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Genmab A/S
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Genmab A/S's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Genmab A/S Snapshot
    • Genmab A/S Overview
    • Key Information
    • Key Facts
  • Genmab A/S - Research and Development Overview
    • Key Therapeutic Areas
  • Genmab A/S - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Genmab A/S - Pipeline Products Glance
    • Genmab A/S - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Genmab A/S - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Genmab A/S - Drug Profiles
    • teprotumumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tisotumab vedotin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HuMax-AXL-ADC
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IDD-004
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody 1 for Central Nervous System Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody 2 for Central Nervous System Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody 3 for Central Nervous System Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Mononclonal Antibody 1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Mononclonal Antibody 2 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Mononclonal Antibody Conjugate for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Genmab A/S - Pipeline Analysis
    • Genmab A/S - Pipeline Products by Target
    • Genmab A/S - Pipeline Products by Route of Administration
    • Genmab A/S - Pipeline Products by Molecule Type
    • Genmab A/S - Pipeline Products by Mechanism of Action
  • Genmab A/S - Recent Pipeline Updates
  • Genmab A/S - Dormant Projects
  • Genmab A/S - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • HuMax-CD74-ADC
      • teprotumumab
  • Genmab A/S - Company Statement
  • Genmab A/S - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Genmab A/S, Key Information
  • Genmab A/S, Key Facts
  • Genmab A/S - Pipeline by Indication, 2016
  • Genmab A/S - Pipeline by Stage of Development, 2016
  • Genmab A/S - Monotherapy Products in Pipeline, 2016
  • Genmab A/S - Partnered Products in Pipeline, 2016
  • Genmab A/S - Partnered Products/ Combination Treatment Modalities, 2016
  • Genmab A/S - Out-Licensed Products in Pipeline, 2016
  • Genmab A/S - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Genmab A/S - Phase II, 2016
  • Genmab A/S - Phase I, 2016
  • Genmab A/S - Preclinical, 2016
  • Genmab A/S - Pipeline by Target, 2016
  • Genmab A/S - Pipeline by Route of Administration, 2016
  • Genmab A/S - Pipeline by Molecule Type, 2016
  • Genmab A/S - Pipeline Products by Mechanism of Action, 2016
  • Genmab A/S - Recent Pipeline Updates, 2016
  • Genmab A/S - Dormant Developmental Projects,2016
  • Genmab A/S - Discontinued Pipeline Products, 2016
  • Genmab A/S, Subsidiaries

List of Figures

  • Genmab A/S - Pipeline by Top 10 Indication, 2016
  • Genmab A/S - Pipeline by Stage of Development, 2016
  • Genmab A/S - Monotherapy Products in Pipeline, 2016
  • Genmab A/S - Partnered Products in Pipeline, 2016
  • Genmab A/S - Out-Licensed Products in Pipeline, 2016
  • Genmab A/S - Pipeline by Target, 2016
  • Genmab A/S - Pipeline by Route of Administration, 2016
  • Genmab A/S - Pipeline by Molecule Type, 2016
  • Genmab A/S - Pipeline Products by Mechanism of Action, 2016
Back to Top